It took 18 months, but Regado Biosciences has finally closed on a new round of financing.

The Durham-based company that is developing technology from Duke University has closed on a “D” round of financing totaling just over $21.5 million. Regado has been raising the funding since December 2009.

The news was disclosed in a filing with the SEC.

Eight investors participated.

Regado is developing a DNA-based system to control bleeding. It is still involved in clinical trials. The technology could present an alternative to such drugs as Heparin and Coumadin, which help prevent heart attacks, strokes and deep-vein thrombosis but also increase the risk of uncontrolled bleeding.

Triangle-based Aurora Funds is one of Regado’s investors.

Other investors in Regado include Caxton Advantage Life Sciences Fund, Quaker BioVentures,Domain Associates and several individuals.

Regado raised $23 million in 2007 and $20 million in 2005.

Get the latest news alerts: Follow WRAL Tech Wire at Twitter.